Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.
Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.
Looking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。